

ASX Announcement

Share Purchase Plan Closing

MELBOURNE Australia, 8 August 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, , would like to remind all eligible shareholders that the Share Purchase Plan (SPP), announced on 16 July 2018, closes at 5pm AEST this Friday 10 August 2018.

To participate, please ensure all documents and application monies are received by 5pm AEST this Friday 10 August 2018.

Pursuant to the SPP Terms and Conditions, shareholders can apply for up to \$15,000 worth of shares, at the price of \$0.30, under the same terms offered to institutional investors during the Company's recent Placement.

Please refer to the SPP documentation posted to shareholders and announced on the 16th July for all important information.

If you did not receive your personalised acceptance form in the mail or if you have any questions, please contact AdAlta's Share Registry - Automic Share Registry Services, on 1300 288 664 (Local) or +61 2 9698 5414 (International) between 8.30am and 5.30pm (AEST) Monday to Friday.

Full details of the SPP Offer are available in the [SPP Offer booklet](#) and a [Q&A session on the SPP](#) are available on the Company's website (www.adalta.com.au).

-ENDS-

Notes to Editors
About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:**AdAlta Limited**

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au